TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England
28 juin 2017 09h00 HE
|
TESARO, Inc.
WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D.,...
TESARO Joins Healthcare Businesswomen’s Association as Corporate Partner
26 juin 2017 16h15 HE
|
TESARO, Inc.
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen’s Association (HBA) as a...
TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference
07 juin 2017 16h30 HE
|
TESARO, Inc.
WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global...
TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
03 juin 2017 18h30 HE
|
TESARO, Inc.
Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
25 mai 2017 16h15 HE
|
TESARO, Inc.
Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community
22 mai 2017 09h01 HE
|
TESARO, Inc.
WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the results of the Our Way Forward survey – a national...
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
11 mai 2017 02h01 HE
|
TESARO, Inc.
WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc’s (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access...
TESARO Announces First-Quarter 2017 Operating Results
09 mai 2017 16h05 HE
|
TESARO, Inc.
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical...
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
01 mai 2017 08h30 HE
|
TESARO, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
27 avr. 2017 08h15 HE
|
TESARO, Inc.
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...